Moderna has now re-rated 43% in a single month, yet the short base has not just survived the rally — it has grown through it.
Short interest has climbed to 15.4% of the free float, edging up roughly 3% over the past month even as the stock logged its best run in years. That's not a covering trade. That's a doubling-down: bears absorbed a unanimous FDA advisory committee vote on mRNA-1010, a Science Day loaded with oncology pipeline news, and a 12.6% single-session gap — and still added to positions. The ORTEX short score reinforces the picture, ticking up to 71 this week from 68.7 a week ago, its highest reading in the recent data window. Days-to-cover on the official FINRA tally sits at 10.5, meaning any forced unwind would take nearly two trading weeks to clear at normal volumes.
The lending market, however, tells a completely different story from the short interest level. Availability is running at 233% — more than two shares available to borrow for every one already lent out. Cost to borrow is just 0.51%, barely above its 30-day range. This is not a squeeze setup. Shorts can add, hold, or cover with minimal friction. The elevated short interest reflects a genuine fundamental disagreement, not a trapped position.
Options traders have quietly shifted toward the bull side. The put/call ratio has dropped to 0.85, more than two standard deviations below its 20-day average of 0.91. That's the most bullish options reading in the data window and sits closer to the 52-week low of 0.70 than to the 52-week peak of 1.18. Call volume has accelerated through the week, consistent with investors reaching for upside exposure after the FDA catalyst rather than hedging against downside.
The Street remains structurally divided in a way that neatly captures the bull/bear impasse. Piper Sandler raised its target to $77 on June 26 — the only firm with a target above the current price. B of A Securities, maintaining its Underperform, raised its target to just $34 in early June. Goldman Sachs and UBS both sit at Neutral with targets of $49 and $45 respectively, implying the consensus mean of $44 now represents a discount to where the stock actually trades. That inversion — the Street's average target roughly 35% below the current price — is a rare configuration. It either means the rally has overshot analyst models, or models need a substantial reset before the next earnings print on August 6. The bull case centres on mRNA's validated platform and oncology optionality; the bear case points to a still-loss-making business, negative EPS, an EPS momentum rank in just the 14th percentile on a 30-day basis, and execution risk across a 35-candidate pipeline that recently absorbed a CMV vaccine failure.
On the institutional side, FMR (Fidelity) added 17.6 million shares in the quarter through April, taking its stake to 11.5% — by far the largest institutional move in the holder table. Capital Research added 5.9 million shares through late May. These are not passive index adjustments. They are active conviction bets being placed on the same side as the rally, while short sellers add in the opposite direction. The insider picture is more cautious: Moderna's president sold $2.7 million worth of stock on June 15 at $51.37, well below current levels, alongside smaller executive sales in early June. Those transactions were executed at prices 25% below where the stock closed the week — a notable gap that suggests insiders were not anticipating the magnitude of the move that followed.
With Q1 earnings confirming a positive one-day and five-day reaction, and Q2 results set for August 6, the next key focal point is how the Street's consensus targets adjust to close the gap with a stock that has firmly outrun the models — and whether 10.5 days of short cover pressure becomes relevant if those revisions arrive before shorts get the chance to reassess their position.
See the live data behind this article on ORTEX.
Open MRNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
